Innate immunity, toll-like receptors, and diabetes

Current Immunology Reviews

Volumn 5, Issue 2, 2009, Pages 111-121

  McInerney, Marcia F ^a   Alexander, Lindsey A ^a   Morran, Michael P ^b   Pietropaolo, Massimo ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; Innate immunity; Toll like receptors; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CHEMOKINE RECEPTOR CCR2; FATTY ACID; FREUND ADJUVANT; GAMMA INTERFERON; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; RETINOIC ACID INDUCIBLE PROTEIN I; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOIMMUNITY; COLONY FORMING UNIT; CYTOKINE PRODUCTION; DIABETES MELLITUS; HELICOBACTER INFECTION; HUMAN; HYPERGLYCEMIA; INFECTION; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIGAND BINDING; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 68549119124     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339509788167038     Document Type: Review

References (155)

1. Thompson G. DR antigens and susceptibility to insulin-dependent diabetes. Am J Hum Genet 1984; 36: 1309-17.
2. Cucca F, Lampis R, Congia M, et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum Mol Genet 2001; 10: 2025-37.
3. Bell G, Horita S, Karam J. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984; 33: 176-83.
4. Barratt BJ, Payne F, Lowe CE, et al. Remapping the Insulin Gene/ IDDM2 Locus in Type 1 Diabetes. Diabetes 2004; 53: 1884-9.
5. Nistico L, Buzzetti R, Pritchard L, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996; 5: 1075-80.
6. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
7. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53: 3020-3.
8. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-8.
9. Smyth D, Cooper J, Bailey R, et al. A genome-wide assoication study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006; 38: 617-9.
10. Todd JA, Bell JI, McDevitt HO. HLA-DQbeta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604.
11. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007; 56: 1189-97.
12. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 727-38.
13. Katz J, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185-8.
14. Rabinovitch A, Suarez-Pinzon W, Sorenson O. Interleukin-12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 1996; 9: 645-51.
15. Von Herrath M, Oldstone M. Interferon-gamma is essential for destruction of beta-cells and development of insulin-dependent diabetes. J Exp Med 1997; 185: 531-9.
16. Lee K, Amano K, Yoon J. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 1988; 37: 989-91.
17. Jansen A, Homo-Delarche F, Hooijkaas H, et al. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 1994; 43: 667-75.
18. Wong F, Janeway CJ. The role of CD4 and CD8 T cells in type 1 diabetes in the NOD mouse. Res Immunol 1997; 148: 327-32.
19. Yoon J, Jun H, Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta-cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 1998; 127: 109-12.
20. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RDG. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003; 19: 89-100.
21. Rabinovitch A, Suarez-Pinzon W. Cytokines and their roles in pancreatic islet B cell destruction and insulin dependent diabetes mellitus. Biochem Pharmacol 1998; 55: 1139-49.
22. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999; 189: 347-58.
23. Oschilewski U, Kiesel U, Kolb H. Administration of silica prevents diabetes in BB-rats. Diabetes 1985; 34: 197-9.
24. Lee K, Pak C, Amano K, Yoon J. Prevention of lymphocytic thyroiditis and insulitis in diabetes prone BB rats by the depletion of macrophages. Diabetologia 1988; 31: 400-2.
25. Atkinson M, Eisenbarth G. Type 1 Diabetes: new prespectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-9.
26. Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. Br J Obstet Gynaecol 2006; 113: 1141-7.
27. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
28. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
29. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
30. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
31. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
32. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-8.
33. Alexandraki K, Piperi C, Kalofoutis C, et al. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006; 1084: 89-117.
34. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004; 21: 203-7.
35. Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Enodcrin Met 2008; 19: 10-6.
36. Janeway CJ, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
37. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-26.
38. Takeda K, Kaisho T, Akira S. Toll-like Receptors. Annu Rev Immunol 2003; 21: 335-76.
39. Dabbagh K, Lewis D. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003; 16: 199-204.
40. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol 2004; 16: 23-6.
41. Park Y, Park S, Yoo E, Kim D, Shin H. Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci 2004; 1037: 170-4.
42. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 2004; 172: 3173-80.
43. Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11: 138- 45.
44. de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60: 58-67.
45. Rudofsky G, Jr, Reismann P, Witte S, et al. Asp299Gly and Thr399Ile Genotypes of the TLR4 Gene Are Associated With a Reduced Prevalence of Diabetic Neuropathy in Patients With Type 2 Diabetes. Diabetes Care 2004; 27: 179-83.
46. Medzhitov R, Janeway CA. Innate Immunity: The Virtues of a Nonclonal System of Recognition. Cell 1997; 91: 295-8.
47. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
48. Burns E, Bachrach G, Shapira L, Nussbaum G. Cutting edge: TLR2 is required for the innate response to porphyromonas gingivalis: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. J Immunol 2006; 177: 8296-300.
49. Johnson G, Brunn G, Platt J. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23: 15-44.
50. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002; 3: 354-9.
51. Dobrovolskaia MA, Medvedev AE, Thomas KE, et al. Induction of in vitro reprogramming by toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappaB signaling pathway components. J Immunol 2003; 170: 508-19.
52. Muthukuru M, Jotwani R, Cutler CW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 2005; 73: 687-94.
53. Guillot L, Le Goffic R, Bloch S, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and Influenza A Virus. J Biol Chem 2005; 280: 5571-80.
54. Jiang W, Sun R, Wei H, Tian Z. Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc Natl Acad Sci USA 2005; 102: 17077-82.
55. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
56. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4. J Exp Med 2002; 195: 99-111.
57. Buttari B, Profumo E, Mattei V, et al. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005; 106: 3880-7.
58. Nguyen MTA, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-92.
59. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA Is an Endogenous Ligand for Toll-like Receptor 3. J Biol Chem 2004; 279: 12542-50.
60. Brentano F, Schorr O, Gay R, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheum 2005; 52: 2656-65.
61. Godfrey DI, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-83.
62. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-45.
63. Akira S. Toll receptor families: structure and function. Semin Immunol 2004; 16: 1-2.
64. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-25.
65. Hayden M, West A, Ghosh S. NF-kB and the immune response. Oncogene 2006; 25: 6758-80.
66. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460-9.
67. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
68. Honda K, Taniguchi T. IRFs: Master regulators of signaling by Toll-like receptors and cytosolic pattern recognition receptors. Nat Rev Immunol 2006; 6: 644-58.
69. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006; 7: 1250-7.
70. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006; 7: 1266-73.
71. Robinson MJ, Sancho D, Slack EC, Leibund Gut-Landmann S, Sousa CRe. Myeloid C-type lectins in innate immunity. Nat Immunol 2006; 7: 1258-65.
72. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-5.
73. Kato H, Sato S, Yoneyama M, et al. Cell type-specific involvement of RIG-1 in antiviral response. Immunity 2005; 23: 19-28.
74. Martin DA, Elkon KB. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med 2005; 202: 1465-9.
75. Meagher C, Sharif S, Hussain S, et al. Cytokines and chemokines in the pathogenesis of murine type 1 diabetes. Adv Exp Med Biol 2003; 520: 133-58.
76. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7.
77. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 2002; 169: 3914-9.
78. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004; 14: 2217-27.
79. Li H, Sun B. Toll-like receptor 4 in athersclerosis. J Cell Mol Med 2007; 11: 88-95.
80. Edfeldt K, Swedenborg J, Hansson GK, Yan Z. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-61.
81. Xu XH, Shah PK, Faure E, et al. Toll-Like Receptor-4 Is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-8.
82. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
83. Kiechl S, Wiedermann CJ, Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med 2003; 35: 164-71.
84. Ameziane N, Beillat T, Verpillat P, et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61-4.
85. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
86. Lang K, Georgiev P, Recher M, et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3. J Clin Invest 2006; 116: 2456-63.
87. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417-28.
88. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-83.
89. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-a and TNF-b by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-31.
90. Hussain M, Peakman M, Gallati H, et al. Elevated serum levels of macrophage derived cytokines preceed and accompany the onset of IDDM. Diabetologia 1996; 39: 60-9.
91. Mohammad MK, Morran M, Slotterbeck B, et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 2006; 18: 1101-13.
92. Sherry CL, O'Connor JC, Kramer JM, Freund GG. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 MAPK. J Immunol 2007; 178: 663-70.
93. Kaizer EC, Glaser CL, Chaussabel D, et al. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007; 92: 3705-11.
94. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53: 2079-86.
95. Hussain M, Maher J, Warnock T, et al. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia 1998; 41: 343-9.
96. Kim HS, Han MS, Chung KW, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007; 27: 321-33.
97. Wen L, Ley R, Volchkov P, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455: 1109-13.
98. McInerney M, Pek S, Thomas D. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 1991; 40: 715-25.
99. Sadelain M, Qin H, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 39: 583-9.
100. Raine T, Zaccone P, Mastroeni P, Cooke A. Salmonella typhimurium infection in nonobese diabetic mice generates immunomodulatory dendritic cells able to prevent type 1 diabetes. J Immunol 2006; 177: 2224-33.
101. Kolb H, Elliott R. Increasing incidence of IDDM a consequence of improved hygiene? Diabetologia 1994; 37: 729.
102. Like A, Guberski D, Butler L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes 1991; 40: 259-62.
103. Wilberz S, Partke HJ, Dagnaes-Hansen F, Herberg L. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. Diabetologia 1991; 34: 2-5.
104. Yagi H, Matsumoto M, Kishimoto Y, Making S, Harada M. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse: II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. Cell Immunol 1991; 138: 142-9.
105. Shehadeh NN, LaRosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993; 6: 291-300.
106. Tian J, Zekzer D, Hanssen L, et al. Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent Autoimmune Diabetes in Nonobese Diabetic Mice. J Immunol 2001; 167: 1081- 9.
107. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000; 165: 6148-55.
108. Green J, Casabonne D, Newton R. Coxsackie B virus serology and Type 1 diabetes mellitus: a systematic review of published casecontrol studies. Diabet Med 2004; 21: 507-14.
109. Barbu AR, Akusjarvi G, Welsh N. Adenoviral-mediated transduction of human pancreatic islets: importance of adenoviral genome for cell viability and association with a deficient antiviral response. Endocrinology 2005; 146: 2406-14.
110. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. Diabet Med 2005; 22: 340-3.
111. Varela-Calvino R, Peakman M. Enteroviruses and type 1 diabetes. Diabetes Metab Res Rev 2003; 19: 431-41.
112. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-35.
113. Devendra D, Eisenbarth G. Interferon alpha- a potential link in the pahtogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004; 111: 225-33.
114. Alba A, Planas R, Clemente X, et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol 2008; 151: 467-75.
115. Rasschaert J, Ladriere L, Urbain M, et al. Toll-like Receptor 3 and STAT-1 Contribute to Double-stranded RNA+ Interferon-gammainduced Apoptosis in Primary Pancreatic beta-Cells. J Biol Chem 2005; 280: 33984-91.
116. Ellerman K, Richards C, Guberski D, Shek W, Like A. Kilham rat triggers T-cell-dependent autoimmune diabetes in multiple strains of rat. Diabetes 1996; 45: 557-62.
117. Zipris D, Lien E, Xie JX, et al. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005; 174: 131-42.
118. Zipris D, Lien E, Nair A, et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007; 178: 693-701.
119. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
120. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-8.
121. Crook M, Tutt P, Simpson H, Pickup J. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin Chim Acta 1993; 219: 131-8.
122. Spiegelman B, Choy L, Hotamisligil G, Graves R, Tontonoz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/ diabetes. J Biol Chem 1993; 268: 6823-6.
123. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone 2007; 8 (suppl 7): S30-42.
124. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-50.
125. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol-Endoc M 2007; 292: E740-7.
126. Suganami T, Mieda T, Itoh M, et al. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 2007; 354: 45-9.
127. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-25.
128. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346: 739-45.
129. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 84-91.
130. Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-98.
131. Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50: 1267-76.
132. Calvet H, Yoshikawa T. Infections in diabetes. Infect Dis Clin North Am 2001; 15: 407-21.
133. Pozzilli P, Leslie R. Infections and Diabetes: Mechanisms and prospects for prevention. Diabet Med 1994; 11: 935-41.
134. Moutschen M, Scheen A, Lefebvre P. Impaired immune responses in diabetes mellitus: analysis of factors and mechanisms involved. Relevance to increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992; 18: 187-201.
135. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-43.
136. Campus G, Salem A, Uzzau S, Baldoni E, Tonolo G. Diabetes and Periodontal Disease: A Case-Control Study. J Periodontol 2005; 76: 418-25.
137. Gulcelik N, Kaya E, Demirbas B, et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005; 28: 214-7.
138. Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. Review article: An unexpected virus-host interaction- the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 2005; 22: 56-60.
139. Banerjee S, Banerjee M. Diabetes and tuberculosis interface. J Indian Med Assoc 2005; 103: 318-22.
140. Rich J, Lee J. The pathogenesis of Staphyloccus aureus infection in the diabetic mouse. Diabetes 2005; 54: 2904-10.
141. Mastropaolo MD, Evans NP, Byrnes MK, et al. Synergy in Polymicrobial Infections in a Mouse Model of Type 2 Diabetes. Infect Immun 2005; 73: 6055-63.
142. Roberts B, Cech I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. South Med J 2005; 98: 686-92.
143. Triantafilou K, Triantafilou M. Coxsackievirus B4-induced cytokine production in pancreatic cells is mediated through toll-like receptor 4. J Virol 2004; 78: 11313-20.
144. Rothenbacher D, Brenner H, Hoffmeister A, et al. Relationship between infectious burden, systemic inflammatory response, and risk of stable coronary artery disease: role of confounding and reference group. Atherosclerosis 2003; 170: 339-45.
145. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002; 33: 2581-6.
146. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
147. Salvi G, Collins J, Yalda B, et al. Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol 1997; 24: 8-16.
148. Salvi G, Beck J, Offenbacher S. PGE2, IL-1 beta, and TNF alpha responses in diabetics as modifiers of periodontal disease expression. Ann Periodontol 1998; 3: 40-50.
149. Engebretson S, Hey-Hadavi J, Erhardt F, et al. Gingival crevicular fluid levels of interleukin-1beta and glycemic control in pateints with chronic periodontitis and type 2 diabetes. J Periodontol 2004; 75: 1203-8.
150. Shanmugam N, Reddy M, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256-64.
151. Guha M, Bai W, Nadler JL, Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000; 275: 17728-39.
152. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5: 975-9.
153. Hajishengallis G, Sharma A, Russell MW, Genco RJ. Interactions of oral pathogens with toll-like receptors: Possible role in atherosclerosis. Ann Periodontol 2002; 7: 72-8.
154. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2227-36.
155. Gordon S. Do macrophage innate immune receptors enhance atherogensis? Dev Cell 2003; 5: 666-8.